Free Newsletter
Kennedy's best hope may lie in cancer vaccine trial
The general prognosis for anyone diagnosed with malignant glioma is poor. The most common form is glioblastoma multiforme, which swiftly dispatches cancer cells throughout the brain. Patients generally have up to three years to live following diagnosis. Given Senator Ted Kennedy's advanced age, his prognosis would appear to be particularly poor.
One of Senator Kennedy's best chances in defeating the malignant brain tumor that afflicts him could be an experimental vaccine, and reports are already circulating that he may be included in a trial that has extended the lives of some patients by three to six years. The vaccine is designed to attack cancer cells in the body after surgeons remove the brain tumor, preventing or slowing the return of the tumor.
- read the report from the Globe and Mail
Related Articles:
Big Pharma takes an interest in cancer vaccines
Vaccine "renaissance" attracts huge new venture investments
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
